Sirtuin1 (
SIRT1) deacetylase delays and improves many
obesity-related diseases, including
nonalcoholic fatty liver disease (
NAFLD) and diabetes, and has received great attention as a
drug target.
SIRT1 function is aberrantly low in
obesity, so understanding the underlying mechanisms is important for
drug development. Here, we show that
obesity-linked phosphorylation of
SIRT1 inhibits its function and promotes pathological symptoms of
NAFLD. In proteomic analysis, Ser-164 was identified as a major
serine phosphorylation site in
SIRT1 in obese, but not lean, mice, and this phosphorylation was catalyzed by
casein kinase 2 (CK2), the levels of which were dramatically elevated in
obesity. Mechanistically, phosphorylation of
SIRT1 at Ser-164 substantially inhibited its nuclear localization and modestly affected its deacetylase activity. Adenovirus-mediated liver-specific expression of
SIRT1 or a phosphor-defective S164A-SIRT1 mutant promoted
fatty acid oxidation and ameliorated
liver steatosis and
glucose intolerance in diet-induced obese mice, but these beneficial effects were not observed in mice expressing a phosphor-mimic S164D-SIRT1 mutant. Remarkably, phosphorylated S164-SIRT1 and CK2 levels were also highly elevated in liver samples of
NAFLD patients and correlated with disease severity. Thus, inhibition of phosphorylation of
SIRT1 by CK2 may serve as a new therapeutic approach for treatment of
NAFLD and other
obesity-related diseases.